4SC AG (LTS:0R6U) Beta: N/A (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0R6U 4SC AG LTS:0R6U
8 GF Score
Price €6.47
GF Value €226.96
! 7 Warning Signs
View Full Analysis

What is 4SC AG Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-20), 4SC AG's Beta is Not available.

4SC AG  (LTS:0R6U) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

4SC AG Beta Related Terms

4SC AG Beta Historical Data

* Premium members only.

The historical data trend for 4SC AG's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4SC AG Beta Chart

4SC AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.12 0.00 0.00

4SC AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.00 0.00 0.00 0.00
LTS:0R6U
8GF Score
4SC AG LTS:0R6U
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

4SC AG Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Is 4SC AG (LTS:0R6U) Overvalued in 2026?

Based on GuruFocus' analysis, 4SC AG stock appears to be undervalued. The current stock price of €6.47 is trading 97.2% below its estimated GF Value™ of €226.96.

Key valuation signals for LTS:0R6U:

  • Beta: N/A
  • GF Value™: €226.96 vs. price of €6.47 (97.2% below fair value)
  • GF Score™: 8/100 with 7 warning signs

No single metric tells the full story. See the LTS:0R6U stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

4SC AG Business Description

Address Fraunhoferstrasse 22, Planegg-Martinsried, DEU, 82152
4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. Its pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development resminostat and Domatinostat. The geographic area of the company is Germany, the EU, and Other countries, and the majority of the revenue comes from Other Countries.
8GF Score

Get the complete analysis for LTS:0R6U

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.47
Price
€226.96
GF Value